ARTICLE | Company News
Lonza Group AG, Regenicin deal
August 23, 2010 7:00 AM UTC
Regenicin received exclusive, worldwide marketing rights to Lonza's tissue-engineered skin substitute technology. Regenicin plans to submit by year end an application to FDA for a Humanitarian Device ...